| |
How is your lab navigating complex NGS workflows? In this webinar, hear subject matter experts explore how a lab informatics solution with out-of-the-box NGS capabilities delivers real value. View Now.
|
|
Today’s Big NewsSep 11, 2023 |
| By James Waldron Roche has installed “stronger gates” to ensure that drug candidates only make it into phase 3 trials if they have a high chance of success, CEO Thomas Schinecker has revealed. |
|
|
|
By Annalee Armstrong Moderna is doubling down in cancer vaccines and cell therapies with a new Immatics research partnership that could eventually top $1.7 billion in milestones. |
By Gabrielle Masson Madrigal Pharmaceuticals’ CEO Paul Friedman, M.D., is stepping aside so Sanofi’s Bill Sibold can take the reins ahead of a possible FDA greenlight for what would be the first treatment approved for nonalcoholic steatohepatitis (NASH). |
Sponsored by IQVIA With IQVIA’s clinical trial solutions and flexible site support strategies, decentralized trial elementss are being leveraged to enhance patient- centered care as well as support sites through hands- on enablement and implementation of DCT platforms these services. |
By Annalee Armstrong A tiny slice of early-stage data for AstraZeneca’s Daiichi Sankyo-partnered antibody drug conjugates showed the jewel of the collaboration, datopotamab deruxtecan, demonstrated a high objective response and disease control rate when combined with immune checkpoint inhibitor Imfinzi in patients with non-small cell lung cancer. |
By Annalee Armstrong Patients taking Crinetics’ rare growth disease drug were able to shift to the oral medicine from their standard of care injections while maintaining control of a key biomarker and symptoms during a late stage study. |
By Annalee Armstrong As Novartis looks to sell off its eye disease unit, a geographic atrophy program is being discontinued on weak data, shutting down a pipeline of milestone payments related to the 2021 acquisition of Gyroscope Therapeutics. |
By Nick Paul Taylor Merck & Co. has unwrapped a fresh set of clinical data on sotatercept, providing further evidence of the safety and efficacy of the cardiovascular drug candidate ahead of a FDA ruling on whether to approve the jewel of the $11.5 billion Acceleron Pharma buyout. |
By Fraiser Kansteiner At 26 weeks, two daily 60-mg doses of Bristol Myers Squibb's candidate reduced the rate of decline in percent predicted forced vital capacity— a key measure of lung function in patients with progressive pulmonary fibrosis—by 69% versus placebo. |
By Helen Floersh Researchers have found a way to supercharge existing COVID-19 vaccines so they generate a more potent immune response at a lower dose than the ones currently in use, at least in mice. |
By Kevin Dunleavy Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032. The analysts project Novo and Eli Lilly will dominate the market. |
By Andrea Park Patients who underwent Theranos’ fraudulent blood tests at the startup’s dozens of outposts in Walgreens stores are finally getting refunds from the drugstore chain. |
By Noah Tong Several house committees dropped new legislation Friday meant to improve price transparency for patients and employers. Here's what they're proposing. |
By Angus Liu The FDA has raised questions about Alnylam's Onpattro as the company seeks to expand the drug into a much larger group of patients with transthyretin amyloidosis (ATTR). |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
